| pubmed-article:16741301 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16741301 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:16741301 | lifeskim:mentions | umls-concept:C0289174 | lld:lifeskim |
| pubmed-article:16741301 | lifeskim:mentions | umls-concept:C0012727 | lld:lifeskim |
| pubmed-article:16741301 | lifeskim:mentions | umls-concept:C0040399 | lld:lifeskim |
| pubmed-article:16741301 | lifeskim:mentions | umls-concept:C1621296 | lld:lifeskim |
| pubmed-article:16741301 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:16741301 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16741301 | pubmed:dateCreated | 2006-6-2 | lld:pubmed |
| pubmed-article:16741301 | pubmed:abstractText | As part of the radioiodinated 4-amino-N-1-[3-(4-fluorophenoxy)propyl]-4-methyl-4-piperidinyl]5-iodo-2-methoxybenzamide ((123)I-R91150) characterization study, ketanserin challenges were performed on healthy volunteers with the aim of assessing the specificity of (123)I-R91150 binding to subtype 2A of the 5-hydroxytryptamine receptor (5-HT(2A)), the sensitivity of (123)I-R91150 SPECT in measuring ligand displacement, the relationship between ketanserin plasma concentrations and (123)I-R91150 displacement, and the suitability of the cerebellum as a reference region for quantification. | lld:pubmed |
| pubmed-article:16741301 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16741301 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16741301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16741301 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16741301 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:16741301 | pubmed:issn | 0161-5505 | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:HuangD MDM | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:CunninghamVin... | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:LlopJordiJ | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:NucciGianluca... | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:CatafauAna... | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:EerselsJos... | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:PaviaJavierJ | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:BullichSantia... | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:DanusMonicaM | lld:pubmed |
| pubmed-article:16741301 | pubmed:author | pubmed-author:AbanadesSergi... | lld:pubmed |
| pubmed-article:16741301 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16741301 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:16741301 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16741301 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16741301 | pubmed:pagination | 929-37 | lld:pubmed |
| pubmed-article:16741301 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:meshHeading | pubmed-meshheading:16741301... | lld:pubmed |
| pubmed-article:16741301 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16741301 | pubmed:articleTitle | Characterization of the SPECT 5-HT2A receptor ligand 123I-R91150 in healthy volunteers: part 2--ketanserin displacement. | lld:pubmed |
| pubmed-article:16741301 | pubmed:affiliation | Experimental Medical Sciences, Clinical Pharmacology Discovery Medicine, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Barcelona, Spain. | lld:pubmed |
| pubmed-article:16741301 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16741301 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:16741301 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16741301 | lld:pubmed |
